<DOC>
	<DOCNO>NCT01494701</DOCNO>
	<brief_summary>This objectives study evaluate safety , tolerability , pharmacokinetics single dose nusinersen ( ISIS 396443 ) administer intrathecally participant Spinal Muscular Atrophy ( SMA ) .</brief_summary>
	<brief_title>An Open-label Safety , Tolerability , Dose-range Finding Study Nusinersen ( ISIS 396443 ) Participants With Spinal Muscular Atrophy ( SMA )</brief_title>
	<detailed_description>This study conduct protocol register Ionis Pharmaceuticals , Inc . In August 2016 , sponsorship trial transfer Biogen .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<criteria>Key Documented Survival Motor Neuron1 ( SMN1 ) homozygous gene deletion Clinical sign attributable Spinal Muscular Atrophy ( SMA ) Able complete study procedure , measurement visit parent/participant adequately supportive psychosocial circumstance , opinion investigator Estimated life expectancy &gt; 2 year Screening Meets ageappropriate institutional criterion use anesthesia/sedation , use plan study procedure Key Respiratory insufficiency define need invasive noninvasive ventilation 24 hour period Presence gastric feed tube Previous scoliosis surgery scoliosis surgery plan duration study would interfere lumbar puncture ( LP ) injection procedure Hospitalization surgery pulmonary event within last 2 month plan study Presence untreated inadequately treat active infection require systemic antiviral antimicrobial therapy History brain spinal cord disease would interfere LP procedure cerebrospinal fluid ( CSF ) circulation Presence implant shunt drain CSF implanted Central Nervous System ( CNS ) catheter History bacterial meningitis Clinically significant abnormality hematology clinical chemistry parameter Treatment another investigational drug , biological agent , device within 1month Screening 5 halflives study agent whichever longer . Any history gene therapy cell transplantation Ongoing medical condition would interfere conduct assessment study . Examples medical disability ( e.g . waste cachexia , severe anemia , etc . ) would interfere assessment safety would compromise ability participant undergo study procedure NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Spinal Muscular Atrophy</keyword>
	<keyword>SMA</keyword>
	<keyword>SMN</keyword>
	<keyword>SMNRx</keyword>
	<keyword>ISIS-SMNRx</keyword>
	<keyword>ISIS-SMN Rx</keyword>
	<keyword>ISIS 396443</keyword>
	<keyword>IONIS-SMNRx</keyword>
	<keyword>IONIS-SMN Rx</keyword>
	<keyword>Spinraza</keyword>
</DOC>